Literature DB >> 19528349

Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation.

Jian Chen1, Masanobu Kobayashi, Stephanie Darmanin, Yi Qiao, Christopher Gully, Ruiying Zhao, Satoshi Kondo, Hua Wang, Huamin Wang, Sai-Ching Jim Yeung, Mong-Hong Lee.   

Abstract

Tumor hypoxia directly promotes genomic instability and facilitates cell survival, resulting in tumors with a more aggressive phenotype. The proto-oncogene pim-1 regulates apoptosis and the cell cycle by phosphorylating target proteins. Overexpression of Pim-1 can cause genomic instability and contribute to lymphomagenesis. It is not clear whether Pim-1 is involved in hypoxia-mediated tumor survival in solid tumors. Here, we show that hypoxia can stabilize Pim-1 by preventing its ubiquitin-mediated proteasomal degradation and can cause Pim-1 translocation from the cytoplasm to the nucleus. Importantly, overexpression of Pim-1 increases NIH3T3 cell transformation exclusively under hypoxic conditions, suggesting that Pim-1 expression under hypoxia may be implicated in the transformation process of solid tumors. Also, blocking Pim-1 function by introduction of dominant negative Pim-1 resensitizes pancreatic cancer cells to apoptosis induced by glucose-deprivation under hypoxia. Introduction of short interfering RNAs for Pim-1 also resensitizes cancer cells to glucose deprivation under hypoxic conditions, while forced overexpression of Pim-1 causes solid tumor cells to become resistant to glucose deprivation. Moreover, dominant negative Pim-1 reduces tumorigenicity in pancreatic cancer cells and HeLa xenograft mouse models. Together, our studies indicate that Pim-1 plays a distinct role in solid tumor formation in vivo, implying that Pim-1 may be a novel target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528349      PMCID: PMC2708825          DOI: 10.2353/ajpath.2009.080972

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.

Authors:  Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Harri P Mankonen; Michael Lilly; Päivi J Koskinen
Journal:  FEBS Lett       Date:  2004-07-30       Impact factor: 4.124

2.  Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects.

Authors:  Yurij Ionov; Xuan Le; Brian J Tunquist; John Sweetenham; Traci Sachs; John Ryder; Thomas Johnson; Michael B Lilly; Andrew S Kraft
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

3.  Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.

Authors:  M van Lohuizen; S Verbeek; P Krimpenfort; J Domen; C Saris; T Radaszkiewicz; A Berns
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

4.  Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.

Authors:  Meejeon Roh; Bernard Gary; Chisu Song; Nasser Said-Al-Naief; Albert Tousson; Andrew Kraft; Isam-Eldin Eltoum; Sarki A Abdulkadir
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

Review 5.  The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis.

Authors:  A E Greijer; E van der Wall
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

6.  Effect of hypoxia on protein phosphatase 2A activity, subcellular distribution and expression in cerebral cortex of newborn piglets.

Authors:  A C Truttmann; Q Ashraf; O P Mishra; M Delivoria-Papadopoulos
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

7.  The human pim-1 gene is not directly activated by the translocation (6;9) in acute nonlymphocytic leukemia.

Authors:  M von Lindern; T van Agthoven; A Hagemeijer; H Adriaansen; G Grosveld
Journal:  Oncogene       Date:  1989-01       Impact factor: 9.867

8.  Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6.

Authors:  H T Cuypers; G Selten; A Berns; A H Geurts van Kessel
Journal:  Hum Genet       Date:  1986-03       Impact factor: 4.132

9.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Authors:  Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro.

Authors:  Alessio Zippo; Alessandra De Robertis; Monia Bardelli; Federico Galvagni; Salvatore Oliviero
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  32 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

2.  Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Authors:  Dapeng Xu; Michael G Cobb; Lily Gavilano; Sam M Witherspoon; Daniel Williams; Catherine D White; Pietro Taverna; Brian K Bednarski; Hong Jin Kim; Albert S Baldwin; Antonio T Baines
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

Review 3.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

Review 4.  PIM kinase (and Akt) biology and signaling in tumors.

Authors:  Noel A Warfel; Andrew S Kraft
Journal:  Pharmacol Ther       Date:  2015-03-05       Impact factor: 12.310

Review 5.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

6.  The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.

Authors:  Dapeng Xu; Stephen A Allsop; Sam M Witherspoon; Jared L Snider; Jen Jen Yeh; James J Fiordalisi; Catherine D White; Daniel Williams; Adrienne D Cox; Antonio T Baines
Journal:  Carcinogenesis       Date:  2011-01-24       Impact factor: 4.944

Review 7.  Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling.

Authors:  Kimberlee M Fischer; Christopher T Cottage; Mathias H Konstandin; Mirko Völkers; Mohsin Khan; Mark A Sussman
Journal:  J Mol Cell Cardiol       Date:  2011-01-19       Impact factor: 5.000

8.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

9.  PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.

Authors:  Noel A Warfel; Alva G Sainz; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

10.  Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.

Authors:  Ulrike Weirauch; Nadine Beckmann; Maren Thomas; Arnold Grünweller; Kilian Huber; Franz Bracher; Roland K Hartmann; Achim Aigner
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.